Turning an 'Achilles' Heel' into an asset - Activation of HIF-1α during angiostatic therapy will increase tumor sensitivity to iron-catalyzed oxidative damage

Medical Hypotheses

Volumn 61, Issue 4, 2003, Pages 509-511

  McCarty, M F ^a  

^a Pantox Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIC AGENT; ANTIMALARIAL AGENT; ARTEMISININ; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CATALYSIS; DRUG EFFECT; DRUG MEGADOSE; HUMAN; IRON THERAPY; MUTATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

EID: 0345598876     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00229-9     Document Type: Article

References (16)

1. Semenza G. L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15: 551-578.
2. Blagosklonny M. V. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int J Oncol 2001; 19: 257-262.
3. Ponka P., Lok C. N. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999; 31: 1111-1137.
4. Lok C. N., Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem 1999; 274: 24147-24152.
5. Bianchi L., Tacchini L., Cairo G. HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res 1999; 27: 4223-4227.
6. Elliott R. L., Elliott M. C., Wang F., Head J. F. Breast carcinoma and the role of iron metabolism. A cytochemical, tissue culture, and ultrastructural study. Ann NY Acad Sci 1993; 698: 159-166.
7. Weinberg E. D. The role of iron in cancer. Eur J Cancer Prev 1996; 5: 19-36.
8. Yang D. C., Wang F., Elliott R. L., Head J. F. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer. Anticancer Res 2001; 21: 541-549.
9. Kamchonwongpaisan S., Meshnick S. R. The mode of action of the antimalarial artemisinin and its derivatives. Gen Pharmacol 1996; 27: 587-592.
10. Moore M. C., Lai H., Li J. R., Ren R. L., McDougall J. A., Singh N. P. et al. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett 1998; 98: 83-87.
11. Singh N. P., Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 2001; 70: 49-56.
12. Lai H., Singh N. P. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 1995; 91: 41-46.
13. Kondo K., Kaelin W. G. J. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001; 264: 117-125.
14. Maxwell P. H., Pugh C. W., Ratcliffe P. J. Insights into the role of the von Hippel-Lindau gene product. A key player in hypoxic regulation. Exp Nephrol 1902; 9: 235-240.
15. Krieg M., Haas R., Brauch H., Acker T., Flamme I., Plate K. H. Upregulation of hypoxia-inducible factors HIF-1alpha and HIF-2 alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000; 19: 5435-5443.
16. Wiesener M. S., Munchenhagen P. M., Berger I., Morgan N. V., Roigas J., Schwiertz A. et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001; 61: 5215-5222.